Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.3%

4 terminated/withdrawn out of 76 trials

Success Rate

94.1%

+7.5% vs industry average

Late-Stage Pipeline

46%

35 trials in Phase 3/4

Results Transparency

11%

7 of 64 completed trials have results

Key Signals

4 recruiting7 with results

Enrollment reporting

Analytics

Phase 4
25(39.7%)
Phase 3
10(15.9%)
Phase 2
10(15.9%)
N/A
9(14.3%)
Phase 1
7(11.1%)
Phase 2/3
2(3.2%)
63Total
Phase 4(25)
Phase 3(10)
Phase 2(10)
N/A(9)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (76)

Showing 20 of 76 trials
NCT05764876Phase 3Completed

Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

Role: lead

NCT06766825Phase 2Completed

Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

Role: lead

NCT07530757Not ApplicableRecruiting

SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition

Role: lead

NCT07792070Not ApplicableCompleted

Pilot Study to Evaluate the Decentralization of Patient Care Among People With HIV in Out-of-hospital Settings

Role: lead

NCT05069974Phase 3Completed

Alternative Antibiotics for Syphilis

Role: lead

NCT07264686Phase 2Active Not Recruiting

Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial

Role: lead

NCT05562323Recruiting

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study

Role: lead

NCT07028385Phase 2Completed

Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

Role: lead

NCT07267390Completed

Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts

Role: lead

NCT07534267Not Yet Recruiting

Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea

Role: collaborator

NCT06315894Not ApplicableCompleted

Supervised Computerized Active Program for People With Post-COVID Syndrome (SuperCAP Study)

Role: lead

NCT06519357Phase 2Active Not Recruiting

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Role: lead

NCT07197164Phase 2Recruiting

Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients

Role: lead

NCT05780073Phase 2Completed

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

Role: collaborator

NCT05303402Phase 2/3Completed

A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

Role: collaborator

NCT06185452Phase 4Completed

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

Role: lead

NCT03029689Phase 3Completed

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

Role: lead

NCT06607588Recruiting

Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Role: lead

NCT04753788Completed

Evaluation of a LAMP Assay for T. Pallidum. Pertenue

Role: collaborator

NCT06643897Not ApplicableCompleted

Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina.

Role: lead